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Accepted 14 May 2013; Published online 17 August 2013AbstractObjectives: Selection bias in caseecontrol studies occurs when control selection is inappropriate. However, selection bias due to im-
proper case sampling is less well recognized. We describe how to recognize survivor bias (i.e., selection on exposed cases) and illustrate this
with an example study.
Study Design and Setting: A caseecontrol study was used to analyze the effect of statins on major bleedings during treatment with
vitamin K antagonists. A total of 110 patients who experienced such bleedings were included 18e1,018 days after the bleeding compli-
cation and matched to 220 controls.
Results: A protective association of major bleeding for exposure to statins (odds ratio [OR]: 0.56; 95% confidence interval: 0.29e1.08)
was found, which did not become stronger after adjustment for confounding factors. These observations lead us to suspect survivor bias. To
identify this bias, results were stratified on time between bleeding event and inclusion, and repeated for a negative control (an exposure not
related to survival): blood group non-O. The ORs for exposure to statins increased gradually to 1.37 with shorter time between outcome and
inclusion, whereas ORs for the negative control remained constant, confirming our hypothesis.
Conclusion: We recommend the presented method to check for overoptimistic results, that is, survivor bias in caseecontrol
studies.  2014 Elsevier Inc. All rights reserved.
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Caseecontrol studies are commonly used because it is
an efficient way to study rare outcomes. They can be as
credible as randomized studies, when correctly designed
and performed [1]. Cases are those who experience the
event of interest, and controls are a random sample from
the source population from which the cases arose [2]. Se-
lection bias in caseecontrol studies is well known to occur
when control selection is inappropriate [2]. However, selec-
tion of cases can result in bias as well, which is less well
recognized. This selection bias can occur when cases are
selected a long period after the event, and exposed cases
have an increased risk of severe illness or death comparedConflict of interest: None.
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http://dx.doi.org/10.1016/j.jclinepi.2013.05.011with nonexposed cases [3]. In this article, we provide pro-
cedures to check for possible selection bias of cases and il-
lustrate this with an example of a caseecontrol study on the
association of statin use and bleeding risk during treatment
with vitamin K antagonists.2. Methods
The study used to illustrate this bias is the ‘‘factors in oral
anticoagulation safety (FACTORS)’’ caseecontrol study,
which has been described before [4]. Briefly, cases reported
a nontraumatic (nonfatal) major bleeding complication, dur-
ing treatment with vitamin K antagonists (oral anticoagu-
lants). Major bleeding was defined as a bleeding leading to
hospitalization, a sudden hemoglobin decrease of higher than
1.25 mmol/L, or an intracranial, intra-abdominal, muscle,
joint, or intraocular bleeding. These bleedings occurred be-
tween 1999 and 2001, and because vitamin K antagonists
are characterized by a narrow therapeutic index, careful
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 Selective survival in cases can occur in retrospec-
tive caseecontrol studies. To detect selective sur-
vival, we propose to stratify on time between the
event and inclusion in the study of the cases and,
if available, also to use a negative control.
 Our case-control study showed a protective assoca-
tion of statin use towards major bleeding during
treatment with vitamin K antagonists. However,
this protective association could be explained by
the sampling method.
 These results reinforce that caution is warranted
when interpreting an observational study that re-
ports protective effects of statins on disease out-
comes when patients had to survive until inclusion.
monitoring is necessary. In the Netherlands, this is per-
formed by anticoagulation clinics [5].
For every case, one to four controls without major bleed-
ing event were matched on anticoagulation clinic, age, in-
dication of anticoagulation, sex, vitamin K antagonist
type (acenocoumarol or phenprocoumon), and whether
treatment with vitamin K antagonists stopped before blood
collection. Cases and controls were interviewed, and blood
was drawn for testing on genetic variants [4]. Inclusion of
cases took place 18e1,018 days after the major bleeding
event (on average 425 days).
Cases and controls were considered statin users when they
reported using this medication at time of the bleeding event
(for cases) and during the interview (for controls). Odds ra-
tios (ORs) with 95% confidence intervals (95% CIs) were
calculated by means of conditional logistic regression, and
were adjusted for comorbidity (diabetes and hypertension)
and use of antiplatelet drugs. Written informed consent was
obtained from all subjects, and the study was approved by
the institutional review boards of the LeidenUniversityMed-
ical Center and the AcademicMedical Center in Amsterdam.
All statistical analyses were performed in SPSS 17.0 for win-
dows (SPSS, Inc., Chicago, IL).3. Results
Complete data of the 110 cases and 220 controls were
available, except for data on blood group (unavailable in
10 subjects). Clinical characteristics are shown in
Table 1. Among both cases and controls, statin users suf-
fered more frequently from comorbid conditions and used
antiplatelet drugs more frequently.
The OR of developing a major bleeding event in statin
vs. nonstatin users was 0.56 (95% CI: 0.29e1.08;
Table 2). We expected that adjustment for comorbidityand use of antiplatelet drugs would lead to an even stronger
protective risk estimate, as these confounding factors in-
crease the risk for bleeding complications [6] and are re-
lated to statin treatment. However, after adjustment for
comorbidity and use of antiplatelet drugs, no stronger pro-
tective risk estimate was observed (OR: 0.53, 95% CI:
0.27e1.03).
These findings were somewhat counterintuitive: first of
all, statins gave a nearly 50% risk reduction of major bleed-
ing, even if the indications for which statins are prescribed
give an increased risk of major bleeding events. Second, ad-
justment for these confounders did not lead to a stronger
protective risk estimate. We could have concluded that sta-
tins are powerful drugs, but instead hypothesized that this
result might be biased.
Survivor bias occurs when exposed cases are less likely
to take part in a study (e.g., because they died or became
severely ill) than unexposed cases. This could mean that ex-
posed cases in this study (i.e., patients who experienced
a bleeding event and used statins) were less likely to parti-
cipate (because of death or severe illness) when time be-
tween the event and inclusion in the study increased.
Therefore, time between bleeding event and inclusion was
taken into account because with more time between a bleed-
ing event and inclusion the higher the possibility that a po-
tential (exposed) case was not able to participate in our
study. Therefore, selected cases (with their matched con-
trols) were stratified on time between the bleeding event
and inclusion (less than 2.00, 1.75, 1.50, 1.25, and less than
1.00 year). We saw that ORs increased gradually from 0.56
(95% CI: 0.29e1.08) to 1.34 (95% CI: 0.52e3.42) when
cases were included within 3 and 1 year(s) after the bleed-
ing event, respectively. After adjustment for comorbidity,
this pattern remained the same (Table 2).
Although this stratified analysis suggests that our results
were due to survivor bias, numbers were small, which may
have led to this finding by chance. We therefore decided to
explore this potential bias further, and repeated the analy-
sis, only this time using exposure to blood group non-O
as a ‘‘negative control,’’ meaning an exposure that, al-
though related to the outcome, is not related to increased
risk of death or severe illness [7]. Risk estimates should re-
main stable with increasing time between the event and in-
clusion in the study to confirm our hypothesis of survivor
bias. Indeed, the OR for major bleeding complications in
patients with blood group non-O as compared with blood
group O was 0.70 (95% CI: 0.43e1.14), and remained sta-
ble after stratifying on time between the major bleeding
event and inclusion (Table 2).4. Discussion
We showed that an association found in a straightforward
analysis of a caseecontrol study can be biased due to selec-
tive survival of the cases. In our example, cases with major
Table 1. Clinical characteristics by cases or controls and statin use
Parameters
Cases (n [ 110) Controls (n [ 220)
Statin users (n [ 18) Nonstatin users (n[ 92) Statin users (n [ 56) Nonstatin users (n[ 164)
% Mean (SD) % Mean (SD) % Mean (SD) % Mean (SD)
Age, yr 69 (10) 67 (12) 67 (10) 70 (11)
Men 94 53 71 55
Body mass index, kg/m2 26.6 (3.4) 25.2 (4.0) 27.2 (4.2) 25.8 (3.8)
Positive smoking history 83 78 88 66
Hypertension 28 30 34 35
Diabetes 33 9 21 14
Antiplatelet drugs 6 4 4 1
Cancer 28 14 13 10
Years of treatment 6.6 (5.9) 5.1 (6.2) 2.9 (4.3) 2.9 (4.4)
Abbreviation: SD, standard deviation.
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pate in our study in the period after the event than cases
who did not use statins, resulting in finding a 43% risk re-
duction of major bleeding during treatment with vitamin K
antagonists. This could be an important phenomenon that
could occur more frequently in caseecontrol studies. We
confirmed this phenomenon by performing our analysis
for two exposures, but a caveat remains that our study is
small numbered. We therefore tried to compare this finding
with other studies; but to our knowledge, this is the first
time of reporting on the association of statin use and major
bleeding during treatment with vitamin K antagonists.
However, there are many claims that statins have protective
effects for several (non)vascular diseases, including multi-
ples sclerosis, depression, Alzheimer’s dementia, athero-
sclerosis, osteoporosis, AIDS, cancer, and venous
thrombosis [8]. For venous thrombosis, a recent meta-
analysis of observational studies compares statin users with
nonstatin users, and shows a relative risk for venous throm-
bosis of 0.62 (95% CI: 0.45e0.86) [9]. The lowest relative
risks (0.20e0.60) were found in studies that had enrolled
patients who had survived their event until inclusion. All
other studies reported relative risk estimates that were
closer to unity (0.74e1.02) [9]. The studies with the lowest
relative risks may therefore have suffered from the same
problem, supporting the hypothesis that survivor bias may
be more common and not always recognized as such. This
is a problem, as causality is often inferred from theseTable 2. Association of major bleeding complications by statin use or blood
enrollment
Time between
bleeding event
and enrollment (yr)
Statin use
Experienced/not experienced
cases and controls Odds ratioa (95% CI) Od
Any time 18/92, 56/164 0.56 (0.29e1.08) 0.
!2.00 18/89, 56/158 0.56 (0.29e1.08) 0.
!1.75 18/79, 53/140 0.60 (0.31e1.17) 0.
!1.50 17/69, 45/130 0.74 (0.37e1.51) 0.
!1.25 13/46, 30/89 1.01 (0.46e2.23) 1.
!1.00 10/25, 18/54 1.34 (0.52e3.42) 1.
Abbreviation: CI, confidence interval.
a Based on conditional logistic regression.
b Based on conditional logistic regression and adjusted for diabetes, hystudies, which may lead to advice to prevent venous throm-
bosis with statins [10].
Although we showed how to detect survivor bias, a pos-
sible limitation of our method (stratification on time be-
tween outcome and inclusion in the study, preferably
repeated for a negative control) remains that it cannot dis-
tinguish survivor bias from a possible temporal biological
effect of the exposure. To distinguish bias and a temporal
effect, one should first look into the biology of the exposure
toward the outcome. For this study, it seems that stratifica-
tion on time is a good method to study survivor bias, as it is
biologically implausible that statins do increase the risk for
bleedings in the first year of use and then become protec-
tive. A limitation of our example study is that numbers be-
came small, especially after stratification on time between
bleeding event and inclusion of cases. Therefore, the risk
estimate (that was not more protective after adjustment
for confounding factors in the stratified analyses) should
be interpreted with caution.
A way to overcome issues of survivor bias includes re-
striction of the analysis to cases who were included within
a certain period in the study (dependent on the exposure
and outcome). This analysis would be preferable when sur-
vivor bias is deemed as present. A negative control (when
available) could be used to verify the presence of the bias
if these are likely to occur due to chance, as was the case
in our study. Another solution could be a study design
where the exposure (statin use) and the outcome (majorgroup non-O, stratified on time between bleeding complication and
Blood group non-O
ds ratiob (95% CI)
Experienced/not experienced
cases and controls Odds ratioa (95% CI)
53 (0.27e1.03) 59/50, 133/78 0.70 (0.43e1.14)
55 (0.28e1.08) 56/50, 129/76 0.68 (0.42e1.11)
59 (0.30e1.20) 51/45, 115/69 0.71 (0.43e1.17)
71 (0.34e1.48) 44/41, 106/63 0.68 (0.40e1.17)
00 (0.42e2.36) 29/29, 73/41 0.58 (0.30e1.12)
37 (0.50e3.81) 17/18, 44/25 0.48 (0.19e1.24)
pertension, and antiplatelet drugs.
235N. van Rein et al. / Journal of Clinical Epidemiology 67 (2014) 232e235bleeding) are not related to inclusion in a study, for exam-
ple, a cohort study.
In summary, when both the exposure and outcome are
related to death or severe illness, overoptimistic associa-
tions could be found in caseecontrol studies. Therefore,
we recommend using the method presented in this study
(i.e., stratification on time between the event and inclu-
sion in the study, preferably for both the exposure of in-
terest and, in case of low numbers, also repeated in
a negative control) to check for selective survival in
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